Skip to content
AnalystLens

DXCM · DEXCOM INC

50 filings

10-Q

DXCM 10-Q Quarterly Reports

DEXCOM INC - 50 quarterly reports

Filing record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’16Jun ’16
  2. Restructuring8-K · Feb ’19Feb ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Oct ’25Oct ’25
  1. 2026-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2026

    DexCom, Inc. (DXCM) reported strong financial performance for the second quarter and first half of 2026, demonstrating significant revenue and profit growth. The company's continuous glucose monitoring (CGM) systems continue to drive this expansion, with notable increases in customer base and revenue per customer. Management highlighted improved manufacturing efficiencies and favorable product mix as contributing factors to expanding gross margins. Financially, Dexcom maintained a robust liquidity position, with substantial cash, cash equivalents, and marketable securities. The company also initiated a significant share repurchase program in the second quarter of 2026, signaling confidence in its financial health and commitment to returning value to shareholders. While facing ongoing litigation, the company asserts it is defending vigorously and does not believe any currently pending proceedings will have a material adverse effect on its business.

    Jul 30, 2026
  2. 2026-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2026

    DexCom, Inc. (DXCM) reported a strong first quarter for 2026, demonstrating significant top-line growth and substantial improvements in profitability. Revenue increased by 15% year-over-year to $1.19 billion, driven by increased sales volume of their continuous glucose monitoring (CGM) systems. This revenue growth, coupled with improved manufacturing efficiencies and a favorable product mix, led to a notable expansion in gross profit margin to 62.9% and a substantial 91% increase in operating income. The company also achieved robust net income growth of 89% to $199.5 million, translating to a diluted EPS of $0.51. The balance sheet remains strong, with cash, cash equivalents, and short-term marketable securities totaling $2.42 billion, providing ample liquidity. Operating cash flow saw a significant increase of 186% to $525.6 million, underscoring the company's operational efficiency and cash generation capabilities. Despite ongoing legal proceedings, DexCom appears to be navigating these challenges while continuing to invest in its core business and expand its market reach.

    Apr 30, 2026
  3. 2025-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2025

    DexCom, Inc. (DXCM) reported a strong third quarter for 2025, demonstrating significant year-over-year growth across key financial metrics. Revenue increased by 22% to $1.21 billion, driven by a robust expansion of their customer base and continued demand for their continuous glucose monitoring (CGM) systems. This top-line growth translated into substantial improvements in profitability, with gross profit up 23% and operating income soaring by 60%. Net income more than doubled, increasing by 111% to $283.8 million, indicating enhanced operational efficiency and effective cost management. The company's financial position remains solid, with a significant increase in cash, cash equivalents, and short-term marketable securities to $3.32 billion. This robust liquidity provides DexCom with ample resources to fund ongoing operations, capital expenditures, and strategic initiatives, including ongoing product development and potential expansion into new markets. The successful launch of the Stelo biosensor and the FDA clearance for the Dexcom G7 15 Day CGM System further bolster the company's product portfolio and market reach. Despite ongoing legal proceedings and regulatory scrutiny, Dexcom has demonstrated impressive financial performance and a positive outlook for continued growth.

    Oct 30, 2025
  4. 2025-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2025

    DexCom, Inc. (DXCM) reported its second-quarter results for the period ending June 30, 2025, demonstrating continued revenue growth and improved profitability. For the three months ended June 30, 2025, the company generated $1.16 billion in revenue, a 15% increase year-over-year, driven by robust sales volume of its disposable sensors and a growing global customer base. Gross profit saw a 10% increase to $688.8 million, though the gross profit margin slightly decreased due to inefficiencies in supply availability, build configurations, and product mix. Operating income significantly improved by 35% to $212.6 million, reflecting strong revenue growth coupled with a decrease in selling, general, and administrative expenses, partly due to lower legal costs. Net income for the quarter rose by 25% to $179.8 million, resulting in diluted earnings per share of $0.45. The company maintained a strong liquidity position, ending the quarter with $2.93 billion in cash, cash equivalents, and short-term marketable securities. Management is focused on product innovation, global expansion, and strategic partnerships, while also navigating regulatory considerations, including an FDA warning letter received in March 2025.

    Jul 30, 2025
  5. 2025-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2025

    DexCom, Inc. (DXCM) reported its first quarter 2025 financial results, showcasing continued revenue growth driven by increased sensor sales volume and a growing global customer base. While revenue saw a healthy 12% year-over-year increase to $1.04 billion, the company experienced a notable decrease in net income to $105.4 million from $146.4 million in the prior year. This decline was primarily attributed to a significant increase in income tax expense, partly due to shortfalls in share-based compensation, and increased cost of sales which compressed gross profit margins. The company ended the quarter with a strong liquidity position, holding $2.70 billion in cash, cash equivalents, and marketable securities. Management highlighted strategic investments in R&D and product development, including the recent FDA clearance of the Dexcom G7 15 Day CGM System and the launch of the Stelo biosensor for prediabetes and Type 2 diabetes. Despite operational efficiencies in selling, general, and administrative expenses, driven by lower legal costs, investors should monitor the impact of increased cost of goods sold and rising tax expenses on future profitability.

    May 1, 2025
  6. 2024-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2024

    DexCom, Inc. (DXCM) reported its financial results for the quarter and nine months ended September 30, 2024. Revenue for the third quarter increased by 2% year-over-year to $994.2 million, and by 13% for the nine-month period to $2,919.5 million. While revenue showed growth, gross profit saw a slight decrease of 5% in the third quarter to $593.8 million, attributed to product and channel mix changes and a non-cash inventory charge. Net income for the third quarter increased by 12% to $134.6 million, resulting in diluted EPS of $0.34. For the nine-month period, net income surged by 49% to $424.5 million, with diluted EPS at $1.04. The company ended the period with a strong liquidity position, including $2.49 billion in cash, cash equivalents, and short-term marketable securities. Operating cash flow for the nine months was robust at $688.1 million. Significant strategic initiatives include the launch of Stelo, a new biosensor for adults with prediabetes and Type 2 diabetes, and continued investment in R&D and international expansion. However, investors should note ongoing patent litigation with Abbott and recent securities class action lawsuits, which introduce considerable uncertainty.

    Oct 24, 2024
  7. 2024-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2024

    DexCom, Inc. reported a strong second quarter for 2024, demonstrating robust growth and profitability. Revenue increased by 15% year-over-year to $1.004 billion, driven by sustained demand for their continuous glucose monitoring (CGM) systems. Gross profit also grew by 15% to $626.7 million, indicating effective cost management alongside sales expansion. The company achieved significant operating income growth of 23%, reaching $158.0 million, and net income surged by 24% to $143.5 million, highlighting operational efficiency and strong earnings power. The company's balance sheet remains healthy, with cash, cash equivalents, and short-term marketable securities totaling $3.12 billion, providing substantial liquidity. Cash flow from operations was particularly strong, showing a 47% increase year-over-year for the quarter, underscoring the company's ability to generate substantial cash from its core business activities. Furthermore, DexCom announced a new $750 million share repurchase program, signaling confidence in its financial position and commitment to returning value to shareholders.

    Jul 25, 2024
  8. 2024-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2024

    DexCom, Inc. reported strong financial performance for the first quarter of 2024, with revenue increasing by 24% year-over-year to $921.0 million. This growth was primarily driven by an increase in sales volume of their continuous glucose monitoring (CGM) systems, adding approximately 600,000 users to their global customer base in the prior year. The company also demonstrated significant profitability improvements, with operating income soaring by 114% and net income more than tripling to $146.4 million, resulting in a diluted EPS of $0.36. Operationally, DexCom continues to invest in research and development to enhance its product offerings and expand into new markets, including individuals with Type 2 diabetes not using insulin. The company's balance sheet remains robust, with cash, cash equivalents, and marketable securities totaling $2.90 billion at the end of the quarter, and positive operating cash flow of $209.2 million underscores its financial strength. However, investors should note ongoing patent litigation with Abbott, which, while currently assessed as not likely to result in a material adverse outcome, remains a point of ongoing legal scrutiny.

    Apr 25, 2024
  9. 2023-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2023

    DexCom Inc. (DXCM) reported strong financial performance for the third quarter and first nine months of 2023, demonstrating significant revenue and profit growth year-over-year. The company's revenue increased by 27% in the third quarter and 24% for the nine-month period, driven by robust sales volume of its continuous glucose monitoring (CGM) systems, particularly with the ongoing adoption of the G7 system. Gross profit also saw healthy increases, up 26% for the quarter and 22% year-to-date, indicating effective cost management alongside sales growth. Financially, DexCom maintains a solid liquidity position with over $3.2 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2023. The company generated substantial positive cash flow from operations, underscoring its operational efficiency. Management remains focused on strategic investments in research and development and manufacturing capabilities to support future growth, including international expansion. Despite ongoing patent litigation with Abbott and various market risks, the company's operational and financial performance indicates a positive trajectory.

    Oct 26, 2023
  10. 2023-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2023

    DexCom, Inc. reported a strong second quarter of 2023, demonstrating robust financial performance with significant year-over-year growth in revenue and profitability. The company saw revenue increase by 25% to $871.3 million, driven by higher sales volumes of its disposable sensors, reflecting continued global customer base expansion. Profitability also showed substantial improvement, with operating income up 66% and net income more than doubling to $115.9 million. This was supported by a gross profit increase of 22% and effective management of operating expenses, despite higher SG&A costs primarily due to increased headcount and marketing initiatives. The company ended the quarter with a healthy cash position of $3.64 billion, indicating strong financial health and ample resources for future growth initiatives. Looking ahead, DexCom anticipates continued growth driven by the increasing incidence of diabetes, demand for digital health technologies, and expansion into new markets and patient populations. However, investors should remain aware of ongoing patent litigation with Abbott and potential pricing pressures from third-party payors. The company's strategic investments in manufacturing capacity, particularly in Malaysia and Ireland, are expected to support future demand.

    Jul 27, 2023
  11. 2023-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2023

    DexCom Inc. reported a solid first quarter for 2023, demonstrating continued revenue growth with a significant increase of 18% year-over-year, reaching $741.5 million. This growth was primarily driven by increased sales volume of disposable sensors. Despite revenue growth, net income saw a substantial decrease of 50% to $48.6 million compared to the same period in the previous year. This decline was influenced by a significant increase in Selling, General, and Administrative (SG&A) expenses, notably driven by higher advertising and marketing costs and legal expenses related to a patent infringement lawsuit. The company ended the quarter with a strong liquidity position, holding $2.57 billion in cash, cash equivalents, and short-term marketable securities, indicating a healthy financial standing.

    Apr 27, 2023
  12. 2022-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2022

    DexCom, Inc. reported strong financial results for the third quarter and the first nine months of 2022, demonstrating robust revenue growth and improved profitability. For the three months ended September 30, 2022, revenue increased by 18% year-over-year to $769.6 million, driven by increased sales volume of disposable sensors. Net income also saw a healthy increase of 16% to $101.2 million. The company's operational efficiency is evident in its gross profit, which grew 11% to $494.2 million, though the gross profit margin decreased slightly year-over-year due to price, product, and channel mix changes. Operating expenses were managed effectively, with a notable decrease in research and development expenses, contributing to a 25% increase in operating income to $147.5 million. The balance sheet remains solid, with a significant cash and short-term marketable securities balance of $2.37 billion as of September 30, 2022. Overall, DexCom continues to exhibit strong growth and operational performance, indicating a positive trajectory. Investors should note the strategic focus on product innovation and market expansion, including the development of its next-generation G7 system, as key drivers for future growth. The company's proactive approach to managing its capital resources and debt obligations, coupled with ongoing investments in R&D, positions it well within the growing diabetes management market.

    Oct 27, 2022
  13. 2022-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2022

    DexCom, Inc. reported robust revenue growth in its Q2 2022 filing, demonstrating continued expansion in its core business. Revenue increased by 17% year-over-year for the quarter and 20% for the six-month period, driven by strong sales volume of their continuous glucose monitoring (CGM) systems, particularly in international markets. While gross profit also saw an increase, the gross profit margin slightly decreased due to price and channel mix shifts. Despite the revenue growth, operating income and net income saw a decline compared to the prior year. This was primarily attributed to increased selling, general, and administrative (SG&A) expenses, driven by higher advertising, marketing, and compensation costs, as well as increased research and development expenses related to new product development and headcount. The company ended the period with a strong cash position of $2.75 billion. A significant subsequent event noted is the authorization of a $700 million share repurchase program, indicating a commitment to returning value to shareholders.

    Jul 28, 2022
  14. 2022-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2022

    DexCom, Inc. (DXCM) reported solid financial results for the first quarter ended March 31, 2022, demonstrating continued revenue growth and improved profitability. The company's revenue increased by 25% year-over-year, driven by strong demand for its continuous glucose monitoring (CGM) systems. This top-line growth translated into a significant 72% increase in net income, highlighting effective cost management and operational efficiency. Financially, Dexcom maintained a strong liquidity position with over $2.69 billion in cash, cash equivalents, and short-term marketable securities. The company's balance sheet remains robust, with total assets growing to $5.06 billion. Management's strategic investments in research and development and manufacturing are expected to fuel future growth, particularly with the upcoming G7 system. Despite some headwinds, such as increased cost of sales and operating expenses, Dexcom's performance indicates a positive trajectory and a commitment to expanding its market leadership in diabetes management technology.

    Apr 28, 2022
  15. 2021-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2021

    DexCom, Inc. reported a solid third quarter of 2021, with revenues reaching $650.2 million, a significant 30% increase year-over-year. This growth was primarily driven by strong sales volume of their disposable sensors, reflecting continued expansion of their global customer base. The company also demonstrated improved profitability, with gross profit rising 31% to $446.9 million and operating income increasing by 26% to $118.3 million. Despite a slight dip in net income to $70.9 million (down 2%), the company's financial health remains robust, with total assets growing to $4.78 billion and stockholders' equity increasing to $2.14 billion. The company continues to invest heavily in research and development, with R&D expenses up 47% year-over-year, indicating a commitment to future product innovation. Financially, DexCom ended the period with a strong liquidity position, holding $1.44 billion in cash and cash equivalents, and $1.25 billion in short-term marketable securities, totaling $2.70 billion. Cash flow from operations was healthy at $336.7 million for the nine months ended September 30, 2021. The company also managed its debt effectively, with convertible notes outstanding but no borrowings against its revolving credit facility. Overall, the report showcases continued top-line growth supported by operational efficiencies and a strong balance sheet, positioning DexCom favorably for future expansion.

    Oct 28, 2021
  16. 2021-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2021

    DexCom Inc. reported a strong second quarter for 2021, with significant year-over-year growth in revenue and profitability. Revenue increased by 32% to $595.1 million, driven by strong sales volume of their continuous glucose monitoring (CGM) systems. This top-line growth translated into substantial improvements in profitability, with gross profit up 47% and operating income up 49%. Key financial highlights include a substantial increase in gross profit margin to 70.1% from 62.9% in the prior year's quarter, demonstrating improved manufacturing efficiencies and pricing power. Net income saw a robust increase of 36% to $62.9 million. The company's balance sheet remains solid, with over $1.15 billion in cash and cash equivalents and no outstanding borrowings on their credit facility, indicating strong liquidity. DexCom continues to invest heavily in research and development, signaling a commitment to future innovation and market leadership in the diabetes management space.

    Jul 29, 2021
  17. 2021-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2021

    DexCom, Inc. (DXCM) reported its first-quarter 2021 financial results, demonstrating robust top-line growth and significant improvements in profitability. Total revenue reached $505.0 million, a 25% increase year-over-year, driven by higher sales volumes of disposable sensors. The company successfully managed its cost of sales, leading to a substantial increase in gross profit to $343.9 million, with a gross profit margin of 68.1%, up from 63.3% in the prior year's quarter. This expansion in gross profit, coupled with controlled operating expenses, resulted in a strong operating income of $45.9 million, up 37% year-over-year. The company also reported a significant jump in net income to $40.3 million, more than doubling from $19.9 million in the first quarter of 2020. This translates to a diluted net income per share of $0.41. Despite a slight decrease in cash, cash equivalents, and short-term marketable securities from the end of the previous fiscal year to $2.63 billion, Dexcom's liquidity remains strong, with $193.6 million available under its revolving credit facility and no outstanding borrowings.

    Apr 29, 2021
  18. 2020-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2020

    DexCom, Inc. (DXCM) reported strong performance for the nine months ended September 30, 2020, with total revenue increasing by 34% year-over-year to $1,357.8 million. This growth was primarily driven by higher sales volumes of their disposable glucose sensors. The company demonstrated significant improvements in profitability, with gross profit increasing by 42% and operating income by a substantial margin (not meaningful due to prior period low base). Net income also saw a dramatic increase from $8.4 million to $138.4 million for the nine-month period. This financial strength is supported by a robust balance sheet, with total assets growing to $3,833.2 million from $2,395.0 million at the end of the prior year, and a substantial increase in cash and cash equivalents to $673.5 million. Financially, DexCom raised considerable capital through the issuance of senior convertible notes in May 2020, amounting to $1.21 billion. The company also effectively managed its debt by repurchasing and converting its 2022 Notes. Management anticipates that existing cash, cash flow from operations, and available credit facilities will be sufficient to meet liquidity needs for at least the next 12 months.

    Oct 27, 2020
  19. 2020-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2020

    DexCom, Inc. reported strong financial performance for the six months ended June 30, 2020, with total revenue increasing by 39% to $856.9 million compared to the same period in the prior year. This growth was primarily driven by increased sales volume of their disposable sensors, reflecting continued customer base expansion. The company also achieved significant improvements in gross profit, which rose by 44% to $540.6 million, with gross margin expanding to 63% from 61% in the prior year. This was attributed to higher revenues and cost savings from manufacturing efficiencies, although partially offset by charges related to manufacturing process shifts and COVID-19 related costs. Financially, DexCom demonstrated a substantial improvement in profitability, moving from a net loss of $37.4 million in the first six months of 2019 to a net income of $66.2 million in the same period of 2020. This turnaround is reflected in the earnings per share, which improved from a loss of $0.41 per share to earnings of $0.71 per share on a basic basis. The company also significantly strengthened its balance sheet, with cash, cash equivalents, and marketable securities increasing by $975.5 million to $2.51 billion as of June 30, 2020, largely due to proceeds from the issuance of senior convertible notes. Management expressed confidence that current liquidity and cash flow generation are sufficient to meet anticipated needs for at least the next 12 months.

    Jul 28, 2020
  20. 2020-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2020

    DexCom, Inc. reported strong financial performance for the first quarter of 2020, with revenues reaching $405.1 million, a significant 44% increase compared to $280.5 million in the same period of 2019. This growth was primarily driven by increased sales volume of disposable sensors. The company also demonstrated improved profitability, with gross profit increasing by 52% to $256.5 million and operating income turning positive at $33.6 million, a substantial improvement from an operating loss of $14.4 million in the prior year's first quarter. Net income for the quarter was $19.9 million, a marked turnaround from a net loss of $26.9 million in Q1 2019. Despite the positive financial results, the company acknowledged the potential impacts of the COVID-19 pandemic, noting that the extent of future impacts remains uncertain. DexCom highlighted its continued investment in research and development and selling, general, and administrative expenses to support future growth. The company's liquidity position remains strong, with $1,510.5 million in cash, cash equivalents, and short-term marketable securities as of March 31, 2020.

    Apr 28, 2020
  21. 2019-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2019

    DexCom, Inc. (DXCM) reported strong top-line growth in its third quarter and the first nine months of 2019, driven by significant increases in revenue. For the third quarter, revenues grew by 49% year-over-year, reaching $396.3 million, and for the nine-month period, revenues increased by 46% to $1.013 billion. This growth was primarily fueled by higher sales volumes of disposable sensors and durable systems, despite some pricing pressures and shifts in product mix. While revenue growth was robust, net income saw a slight decrease of 2% for the third quarter, amounting to $45.8 million, down from $46.6 million in the prior year's quarter. This was largely influenced by increased operating expenses, particularly in research and development and selling, general, and administrative functions, as well as higher interest expenses related to the issuance of new convertible notes. For the nine-month period, net income decreased significantly by 84% to $8.4 million, primarily due to a substantial increase in interest expense from the 2023 convertible notes and a prior year gain from an equity investment. Investors should monitor expense management and the impact of the convertible debt on future profitability.

    Nov 6, 2019
  22. 2019-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2019

    DexCom, Inc. (DXCM) reported its second quarter and first half 2019 financial results. The company experienced significant revenue growth, with a 39% increase year-over-year for the quarter to $336.4 million and a 45% increase for the first half to $616.9 million. This growth was primarily driven by higher sales volumes of their continuous glucose monitoring (CGM) system components, despite some pricing pressure and a shift in product mix. While revenue showed robust expansion, the company reported a net loss of $10.5 million for the quarter and $37.4 million for the first half, compared to a net income of $30.2 million and $6.0 million in the respective prior-year periods. This shift to a loss was influenced by increased operating expenses, particularly in research and development and selling, general, and administrative costs, as well as higher interest expenses related to recent debt issuances. The company's balance sheet reflects an increase in cash and cash equivalents, partially offset by strategic investments in marketable securities and property. A notable change was the adoption of the new lease accounting standard (ASC 842) at the beginning of 2019, which introduced operating lease right-of-use assets and liabilities onto the balance sheet. Management indicated that despite the reported net loss, they believe existing cash, cash equivalents, marketable securities, and their revolving credit facility are sufficient to meet operational needs for at least the next 12 months. The company also highlighted ongoing efforts to scale production capacity and expand internationally.

    Jul 31, 2019
  23. 2019-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2019

    DexCom, Inc. (DXCM) reported its first quarter 2019 financial results, showcasing significant revenue growth year-over-year, though the company continues to operate at a net loss. Total revenues surged by 52% to $280.5 million, driven by strong sales volume of both disposable sensors and durable systems, indicating continued expansion of its customer base globally. Despite the impressive top-line performance, the company's gross margin saw a slight decrease to 60% from 64% in the prior year's quarter, attributed to evolving channel strategies, product mix, and investments in infrastructure for production capacity expansion. Operating expenses also increased, particularly in Research & Development and Selling, General & Administrative areas, contributing to a wider operating loss of $14.4 million. The net loss for the quarter was $26.9 million, or $(0.30) per share. The company maintains a strong liquidity position with over $1.3 billion in cash, cash equivalents, and marketable securities, providing confidence in its ability to fund operations for at least the next 12 months.

    May 1, 2019
  24. 2018-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2018

    DexCom, Inc. (DXCM) reported strong revenue growth in the third quarter and first nine months of 2018 compared to the prior year, driven by increased sales volume of its continuous glucose monitoring (CGM) systems. The company achieved profitability in the third quarter of 2018, a significant turnaround from the losses reported in the same period of 2017. This positive shift is attributed to increased revenue and improved gross margins, partially offset by higher operating expenses, particularly in selling, general, and administrative functions, which are being invested to support growth. The company also recognized substantial income from its equity investment in Tandem Diabetes Care, Inc., further boosting net income. Financially, DexCom ended the quarter with a healthy cash position and a significant increase in both current assets and total assets compared to the prior year-end. While accounts payable and accrued liabilities saw an increase, the company maintains a strong working capital position. The company's liquidity appears sound, with sufficient cash, cash equivalents, and marketable securities to fund operations through at least the next twelve months. The strong operational performance and strategic investments in growth areas suggest a positive trajectory for DexCom.

    Nov 6, 2018
  25. 2018-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2018

    DexCom, Inc. (DXCM) reported a significant increase in revenue for the second quarter and first six months of 2018, driven by higher sales volumes of its continuous glucose monitoring (CGM) systems. Revenue for the three months ended June 30, 2018, was $242.5 million, a 42% increase year-over-year, and for the six months ended June 30, 2018, revenue was $426.9 million, a 36% increase year-over-year. Despite revenue growth, the company reported an operating loss of $4.9 million for the quarter, though this was an improvement from the $13.6 million loss in the prior year's quarter. Net income for the quarter was $30.2 million, a substantial improvement from $2.9 million in the prior year, largely due to a significant unrealized gain from an equity investment in Tandem Diabetes Care, Inc. Key financial highlights include a gross profit margin of 63% for the quarter, which decreased from 69% in the prior year due to increased cost of sales and inventory charges. The company's cash position remains strong, with $300.2 million in cash and cash equivalents as of June 30, 2018. DexCom also highlighted its G6 system's recent FDA approval, which is expected to drive future growth. The company's liquidity is considered sufficient to fund operations through at least August 1, 2019.

    Aug 1, 2018
  26. 2018-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2018

    DexCom, Inc. (DXCM) reported its first quarter 2018 financial results, highlighting significant revenue growth driven by increased sales volume of its continuous glucose monitoring (CGM) systems, particularly disposable sensors. While revenue increased by 29.6% year-over-year to $184.4 million, the company continued to operate at a net loss of $24.2 million for the quarter, an improvement from the $41.7 million loss in the prior year period. This loss is attributed to ongoing investments in research and development and selling, general, and administrative expenses to support business expansion. The company maintained a strong liquidity position with $533.9 million in cash, cash equivalents, and marketable securities as of March 31, 2018, and $195.6 million available under its revolving credit facility. DexCom stated its belief that its current resources will be sufficient to fund operations through at least May 2, 2019. Despite the continued net loss, the revenue growth and improving operational efficiency, as indicated by a stable gross profit margin, suggest positive momentum for the company in the expanding diabetes technology market.

    May 2, 2018
  27. 2017-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2017

    DexCom, Inc. reported its third quarter 2017 financial results, showcasing significant year-over-year revenue growth driven by increased sales volume of its continuous glucose monitoring (CGM) systems, particularly disposable sensors. The company has seen substantial improvements in its financial position, including a significant increase in cash and cash equivalents, largely due to a successful convertible senior notes offering. Despite continued operating losses and an accumulated deficit, management believes its current working capital is sufficient to fund operations through at least September 30, 2018. The company is actively managing its balance sheet, evidenced by the issuance of long-term senior convertible notes and maintaining a strong cash position. The increase in operating expenses, particularly in Selling, General, and Administrative, reflects investments in sales and marketing to support product commercialization and growth. Investors should note the company's ongoing R&D investments aimed at developing next-generation CGM products and its strategic collaborations, such as the one with Verily Life Sciences.

    Nov 1, 2017
  28. 2017-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2017

    DEXCOM INC (DXCM) reported its second-quarter and first-half 2017 financial results, showcasing significant revenue growth driven by increased sales volume of its continuous glucose monitoring (CGM) systems. While the company continues to operate at a net loss, the financial performance indicates progress in scaling operations and expanding market reach. A key development during the quarter was the successful issuance of convertible senior notes, significantly bolstering the company's cash position and providing resources for future growth initiatives, including manufacturing expansion and potential acquisitions. The company also highlighted its ongoing efforts to secure broader insurance reimbursement, a critical factor for sustained commercial success. Operationally, revenue increased by 24.3% year-over-year for the three months ended June 30, 2017, reaching $170.6 million, and by 23.4% for the six months ended June 30, 2017, to $312.9 million. Despite this top-line growth, operating expenses, particularly in research and development and selling, general, and administrative functions, also increased as the company invests in product development and market penetration. The company ended the period with a substantially improved cash balance, largely due to the convertible note issuance, and expressed confidence in its ability to fund operations through at least June 30, 2018.

    Aug 1, 2017
  29. 2017-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2017

    DexCom, Inc. (DXCM) reported its first quarter 2017 results, showing a significant increase in revenue, up 22.5% year-over-year to $142.3 million. This growth was primarily driven by strong sales of disposable sensors and durable systems, reflecting the expanding installed base of their continuous glucose monitoring (CGM) systems, particularly the G4 PLATINUM and G5 Mobile models. Despite revenue growth, the company continued to operate at a net loss, which widened to $41.7 million for the quarter, compared to $19.2 million in the prior year period. This increased loss is largely attributable to substantial investments in research and development ($48.1 million) and selling, general, and administrative expenses ($86.4 million), both of which saw significant increases as the company scaled operations and commercialization efforts.

    May 2, 2017
  30. 2016-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2016

    DexCom, Inc. (DXCM) reported its financial results for the third quarter and first nine months ended September 30, 2016. The company demonstrated significant revenue growth year-over-year, with total revenue increasing by 43.4% to $148.6 million for the third quarter and by 51.3% to $402.1 million for the first nine months. This growth was primarily driven by increased sales volume of disposable sensors and durable systems for their G4 PLATINUM and G5 Mobile continuous glucose monitoring (CGM) systems. Despite strong revenue performance, the company continued to operate at a net loss, reporting a net loss of $18.8 million for the third quarter and $58.2 million for the first nine months. However, cash flow from operations remained positive and showed an increase compared to the prior year, indicating improving operational efficiency in managing working capital and non-cash expenses like share-based compensation. The company also highlighted its growing cash reserves and ample working capital, positioning it to fund operations and growth initiatives through at least September 30, 2017, supported by a new $200 million credit facility. Key strategic developments include ongoing product innovation with the G5 Mobile system and expansion of international operations. The company is actively managing its product pipeline and collaborations, including the significant partnership with Verily Life Sciences. DexCom's balance sheet shows a growing asset base, with an increase in cash and a substantial rise in property and equipment, net, reflecting investments in manufacturing capabilities. While gross profit margins remain healthy, the company continues to invest heavily in selling, general, and administrative expenses to support its growth and commercialization efforts. Investors should monitor the company's path to profitability, continued revenue acceleration, and its ability to effectively manage operating expenses and regulatory requirements in the expanding CGM market.

    Nov 1, 2016
  31. 2016-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2016

    DexCom's Q2 2016 10-Q shows a company in rapid commercial expansion but still deeply loss-making. Total revenue for the quarter rose to $137.3 million from $93.2 million, up roughly 47% year over year, driven by growing disposable sensor volume from the installed base of G4 PLATINUM and G5 Mobile users. Gross profit reached $85.5 million (about 62% gross margin), but was pressured by $3.5 million of receiver-related excess and obsolete inventory charges tied to the February 2016 customer notification over audible alarm failures, which the FDA classified as a voluntary Class 1 recall. Operating expenses grew faster than revenue, with SG&A up 53% and R&D up 49%, so the operating loss widened to $20.1 million from $3.6 million, and net loss per share was $(0.24) versus $(0.05). Share-based compensation of $27.6 million in the quarter is a major contributor to the expense base. The balance sheet and liquidity picture improved on paper but remains thin relative to burn. Cash and marketable securities totaled $115.6 million and working capital was $167.1 million. Management states these resources, together with a new $200.0 million revolving credit agreement entered in June 2016 (with no borrowings outstanding), fund operations through at least June 30, 2017. Operating cash flow was positive at $19.9 million for the six months, but that was supported by non-cash share-based compensation; capital expenditures of $22.0 million for manufacturing expansion (including the new Mesa, Arizona facility) were significant. The company also paid off its term loan in June 2016. Key watch items for investors include the pending Agamatrix patent infringement lawsuit, which management says has no merit and for which no accrual has been recorded; the July 21, 2016 FDA advisory panel vote favoring a non-adjunctive indication for the G5 Mobile, with formal approval still pending; the UnitedHealthcare decision to designate Medtronic as its preferred insulin pump provider, which could hurt partner pump sales from Animas and Tandem; and the continuing lack of Medicare national coverage for CGM devices. Concentration is also notable, with Byram and Edgepark together accounting for about 28% of six-month revenue.

    Aug 2, 2016
  32. 2016-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2016

    DexCom, Inc. (DXCM) reported its first quarter 2016 financial results, showing significant revenue growth compared to the prior year. Total revenues reached $116.2 million, a substantial increase from $72.8 million in Q1 2015, driven by strong sales volumes of disposable sensors and durable systems, reflecting continued growth in their customer base for the G4 PLATINUM and G5 Mobile systems. Despite the revenue surge, the company reported a net loss of $19.2 million for the quarter, an increase from the $12.9 million net loss in Q1 2015. This widened net loss is attributed to increased operating expenses, particularly in research and development and selling, general, and administrative costs, which rose to support revenue growth and product commercialization. The company maintains a strong focus on product development and market expansion, including collaborations like the one with Verily Life Sciences, signaling a commitment to future innovation and growth, though it continues to operate at a loss.

    Apr 27, 2016
  33. 2015-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2015

    DexCom, Inc. (DXCM) reported strong revenue growth for the nine months ended September 30, 2015, with product revenues increasing by 56% to $269.9 million, driven by increased sales volume of its disposable sensors and durable systems for its G4 PLATINUM and G5 Mobile continuous glucose monitoring (CGM) systems. Despite this significant top-line growth, the company continued to operate at a net loss, which widened to $59.1 million for the nine-month period, compared to $23.7 million in the prior year. This increased net loss was largely attributable to a substantial rise in research and development (R&D) expenses, primarily due to a $36.5 million non-cash expense related to the issuance of stock for a collaboration agreement with Google Life Sciences (GLS), alongside higher share-based compensation and salaries. Financially, DexCom's balance sheet shows a growing asset base, with total assets increasing to $256.7 million from $184.6 million at year-end 2014. This growth is supported by increases in cash and cash equivalents, accounts receivable, and inventory. The company maintains a healthy working capital of $144.9 million as of September 30, 2015, and management believes its current resources are sufficient to fund operations through at least September 30, 2016. The company is actively investing in future growth, as evidenced by the significant increase in R&D spending and the strategic collaboration with GLS, indicating a focus on developing next-generation CGM products.

    Nov 4, 2015
  34. 2015-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2015

    DexCom, Inc. (DXCM) reported its financial results for the second quarter and the first half of 2015. The company demonstrated significant revenue growth, with product revenue increasing by approximately 59% year-over-year for the quarter and 58% for the first half. This growth was primarily driven by increased sales volume of their G4 PLATINUM continuous glucose monitoring (CGM) system, particularly disposable sensors. Despite the strong revenue performance, the company continued to operate at a net loss, though the loss narrowed on a per-share basis. Significant investments in research and development, along with increased selling, general, and administrative expenses, contributed to the ongoing net loss. The company maintains a solid liquidity position with approximately $97.5 million in cash, cash equivalents, and marketable securities as of June 30, 2015, and projects sufficient funds to operate through at least June 30, 2016. Management is focused on scaling manufacturing and expanding commercialization efforts, highlighting the growing installed base of customers using their G4 PLATINUM system and the recent launch of the G4 PLATINUM with Share remote monitoring system. Investors should monitor the company's progress in achieving profitability while continuing to expand market share and develop new product iterations.

    Aug 5, 2015
  35. 2015-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2015

    DexCom, Inc. reported increased product revenue of $72.8 million for the first quarter of 2015, a significant rise from $46.7 million in the same period of 2014, driven by strong sales volume of its G4 PLATINUM continuous glucose monitoring system. Despite this revenue growth, the company continued to incur net losses, reporting a net loss of $12.9 million for the quarter, compared to $12.5 million in the prior year. Operating expenses, particularly in research and development and selling, general, and administrative functions, saw increases, reflecting investments in future product development and commercialization efforts. The company's liquidity position remains adequate, with $83.8 million in cash, cash equivalents, and marketable securities as of March 31, 2015, and management believes these resources are sufficient to fund operations through at least March 31, 2016. Key strategic developments include the commercialization of the DexCom G4 PLATINUM with Share remote monitoring system in early 2015, which allows for remote monitoring of glucose information by designated recipients. The company also noted progress in its manufacturing operations and an ongoing focus on expanding its direct sales force and distribution networks. While the company is experiencing substantial revenue growth, the persistent net losses and significant accumulated deficit highlight the ongoing investment phase of its business. Investors should monitor the company's ability to achieve profitability, manage operating expenses, and secure necessary regulatory approvals for future products.

    Apr 29, 2015
  36. 2014-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2014

    DexCom's third-quarter 2014 results show a company in rapid commercial growth but still well short of profitability. Total revenue rose to $69.0 million for the quarter, up from $42.9 million a year earlier (about 61%), driven by product revenue of $67.9 million, up from $42.5 million, as demand for the G4 PLATINUM system and its disposable sensors grew. Gross margin improved meaningfully, with gross profit of $47.2 million versus $27.6 million, but operating expenses grew faster than revenue. Operating expenses rose to $52.2 million, led by sharp increases in SG&A ($33.7 million) and R&D ($18.5 million), largely from headcount, share-based compensation and consulting costs. As a result, the operating loss narrowed only modestly to $5.0 million from $5.8 million, and the net loss was $5.2 million, or $0.07 per share. For the nine months, the net loss was $23.7 million, compared with $27.2 million a year earlier. The balance sheet and cash flow picture improved. Cash and cash equivalents rose to $63.2 million, and cash plus short-term marketable securities totaled $74.9 million, against working capital of $82.8 million. Operating cash flow turned positive at $15.2 million for the nine months, compared with a $2.0 million outflow a year earlier, though this was largely driven by non-cash share-based compensation of $35.7 million. Management states that resources are sufficient through at least September 30, 2015. Investors should note that capital expenditures of $11.6 million, a new San Diego lease totaling about $33 million in rent through 2022, and $26.9 million in purchase commitments all weigh on future cash needs. The company also settled its long-running Abbott patent litigation through a royalty-free cross-license, though a $25 million change-of-control continuation fee applies. Key risks remain significant. The company depends on the G4 PLATINUM system for substantially all product revenue, and reimbursement is still limited because Medicare has not issued a national coverage decision. Distributors Byram and Edgepark accounted for roughly 18% and 11% of nine-month revenue, respectively. The company has also received an FDA warning letter related to medical device reporting, which it has responded to and which remains under FDA review. Its manufacturing relies on several single-source suppliers. Leadership is also set to transition, with Kevin Sayer becoming CEO and Terrance Gregg becoming Executive Chairman effective January 1, 2015.

    Nov 6, 2014
  37. 2014-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2014

    DexCom's Q2 2014 10-Q shows a company still in early commercialization but scaling quickly. Total revenue for the quarter rose to $58.8 million from $35.8 million a year earlier (up about 64%), driven by product revenue of $58.2 million, which reflects growing G4 PLATINUM sales and a larger installed base. Gross margin expanded to roughly 68% (gross profit of $39.9 million), and operating loss narrowed to $5.8 million from $9.9 million. Net loss for the quarter was $6.0 million, or $0.09 per share, versus $10.1 million, or $0.14 per share, in the prior-year quarter. For the first half, operating cash flow turned slightly positive at $3.8 million, compared with a $3.6 million outflow in 2013. The quality of the improvement needs context. Share-based compensation rose sharply to $13.2 million in the quarter, and SG&A grew 49% year over year, so the path to profitability depends on continued revenue growth outpacing a cost base that is still expanding. The company had an accumulated deficit of $493.9 million and liquidity of $61.3 million in cash and short-term securities, plus $15.0 million of undrawn credit. Management states this is sufficient through at least June 30, 2015, but that horizon is short for a company still burning cash on investment spending, and a capital raise or additional debt draw remains a realistic possibility. The filing also contains several items that bear on the investment case. On July 2, 2014, DexCom settled Abbott patent litigation with a royalty-free cross-license, removing a long-running overhang, though the agreement includes a $25 million change-of-control continuation fee. Reimbursement remains the central commercial constraint, since Medicare has not issued a national coverage decision and private payor coverage is still restrictive. Two distributors, Byram and Edgepark, accounted for about 18% and 12% of revenue in the first half, and the company disclosed an FDA warning letter on medical device reporting (MDR) procedures. Leadership is also changing, with CEO Terrance Gregg transitioning to Executive Chairman and Kevin Sayer becoming CEO effective January 1, 2015.

    Aug 6, 2014
  38. 2014-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2014

    DexCom's first-quarter 2014 results show a company in the midst of a commercialization ramp, with strong top-line growth but continued heavy operating losses. Total revenue rose to $47.1 million from $29.6 million, driven by product revenue of $46.7 million (up from $27.8 million) on higher durable system and disposable sensor volume following the October 2012 G4 PLATINUM launch. Gross profit more than doubled to $29.8 million, and gross margin improved to roughly 63% from about 56%, aided by a richer mix of the higher-margin G4 PLATINUM. However, operating expenses grew faster than revenue, with SG&A up 53% to $27.6 million and R&D up 56% to $14.5 million. The operating loss widened to $12.3 million and the net loss to $12.5 million, or $0.17 per share, compared with $11.1 million a year earlier. Liquidity is adequate for the near term but thin relative to the burn profile. Cash, equivalents and short-term marketable securities totaled $57.4 million, against an accumulated deficit of $487.9 million. Working capital was $63.9 million. Management says resources are sufficient through at least March 31, 2015, and the company has $15.0 million still available under its Silicon Valley Bank and Oxford Finance loan facility, plus a $4.0 million Helmsley Trust grant. Operating cash burn narrowed to $2.4 million, helped largely by non-cash share-based compensation of $8.7 million, but investing outflows for manufacturing equipment rose to $3.9 million. Shareholders' equity increased to $90.0 million, primarily from stock issuance and option exercises. The filing also highlights meaningful risks. Abbott Diabetes Care's patent infringement litigation remains stayed but is pending, with Abbott seeking to lift the stay and asserting a new patent. The FDA issued a warning letter on March 14, 2014 regarding Medical Device Reporting administrative deficiencies, and the company responded on April 2. Distributor concentration is significant, with Byram and Edgepark accounting for about 17% and 12% of revenue. Medicare still does not reimburse CGM devices under a national coverage decision. Leadership transition is also planned, with Kevin Sayer set to succeed Terrance Gregg as CEO on January 1, 2015.

    May 1, 2014
  39. 2013-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2013

    DexCom's Q3 2013 10-Q shows a company inflecting toward commercial scale. Total revenue for the quarter rose to $42.9 million from $23.1 million a year earlier, an increase of about 86%, driven by product revenue of $42.5 million (up from $21.1 million) following the October 2012 launch of the G4 PLATINUM system. Gross profit rose to $27.6 million from $8.4 million, and the operating loss narrowed to $5.8 million from $17.3 million. Net loss for the quarter was $6.0 million, or $0.08 per share, versus $17.3 million, or $0.25 per share, a year earlier. For the nine months, net cash used in operations fell to $2.0 million from $22.5 million, a major improvement in cash burn. The balance sheet remains thin. Cash, cash equivalents and short-term marketable securities totaled $47.6 million, plus $1.0 million restricted cash, against an accumulated deficit of $472.8 million and working capital of $54.3 million. Management states that resources are sufficient through at least September 30, 2014, but the company still has no profitable quarter to show and depends on continued revenue growth. Its loan agreement provides up to $28.0 million of additional borrowing capacity, though the $13.0 million term loan draw period was pushed to January through March 2014, which means that access is not yet fully available. Key risks for investors include the pending Abbott patent litigation and related reexamination proceedings, which have not been accrued for, the lack of Medicare national coverage for CGM, reliance on single-source suppliers and manufacturing scale-up, and the concentration of sales through the Edgepark distribution relationship (about 15% of nine-month revenue). The company also disclosed an additional warranty accrual for the G4 PLATINUM system, a point investors should monitor for product quality.

    Nov 6, 2013
  40. 2013-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2013

    DexCom's Q2 2013 10-Q shows a company still in the early commercialization stage but with accelerating top-line growth. Total revenue for the quarter rose to $35.8 million from $23.4 million, a 53% increase, and product revenue reached $35.5 million versus $21.5 million, driven mainly by volume growth and the October 2012 launch of the G4 PLATINUM system. Gross profit nearly doubled to $21.9 million, and the product gross margin widened as higher-margin G4 PLATINUM units gained mix. Despite this, the company still lost $10.1 million in the quarter, or $0.14 per share, compared with a $14.7 million loss a year earlier. Operating expenses grew, with SG&A up 30% to $20.7 million, so the company has not yet reached profitability. Liquidity is the main investor concern. Cash, equivalents and short-term marketable securities totaled $46.4 million at June 30, 2013, with working capital of $53.1 million and an accumulated deficit of $466.8 million. Management says these resources, together with the $35.0 million Loan Agreement and the $4.0 million Helmsley grant, fund operations through at least June 30, 2014. The additional $13.0 million term loan draw was pushed back to January to March 2014, and the company may need to raise more equity or debt, which could dilute shareholders. Net cash used in operations fell sharply to $3.6 million for the first half from $16.5 million a year earlier. The filing also highlights ongoing legal and regulatory risk. Abbott's long-running patent infringement suit remains stayed pending reexamination of seven patents, and no amount has been accrued. Medicare still does not cover CGM devices under a national coverage decision, so reimbursement depends on private payors, and the company relies on several single-source suppliers. Overall, the quarter shows strong commercial momentum, but a path to sustained profitability and long-term funding remains unproven.

    Aug 7, 2013
  41. 2013-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2013

    DexCom's first-quarter 2013 results show a company still in early commercialization but moving closer to the operating breakeven it has targeted. Total revenue rose 47% year over year to $29.6 million from $20.1 million, driven by product revenue of $27.8 million (up from $18.6 million), which management attributes mainly to higher durable system and disposable sensor volume following the October 2012 launch of the G4 PLATINUM system. Gross profit nearly doubled to $16.5 million from $9.4 million, lifting gross margin to roughly 56% from 47%. Operating expenses grew to $27.4 million, led by a $2.7 million increase in SG&A, so the operating loss narrowed to $10.9 million from $15.4 million. The net loss was $11.1 million, or $0.16 per share, compared with $14.1 million, or $0.21 per share, a year earlier. Operating cash burn also improved sharply, with net cash used in operations falling to $4.5 million from $10.2 million, partly because of a $3.2 million collection of receivables from strong Q4 2012 sales. The balance sheet is thinner than the income statement improvement suggests. Cash, cash equivalents and short-term securities totaled $45.3 million, down from roughly $48.7 million at year-end, and working capital was $55.1 million. The company has an accumulated deficit of $456.7 million and says its resources are sufficient only through March 31, 2014, a horizon of about twelve months, so additional financing is a realistic near-term possibility. The company also has a $35 million loan facility with Silicon Valley Bank and Oxford Finance, of which $7.0 million is drawn, with a further $13.0 million term tranche available from June to September 2013. The key risks for investors are the unresolved Abbott patent litigation, which has no accrual, the absence of Medicare national coverage, dependence on a few distributors (Edgepark accounted for about 15% of revenue), and the termination of the Roche collaboration. Taken together, the quarter shows real commercial traction, but sustaining it through the next financing and regulatory milestones will be the central test.

    May 1, 2013
  42. 2012-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2012

    DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended September 30, 2012, reporting on its financial condition and operational results. The company, a medical device manufacturer focused on continuous glucose monitoring (CGM) systems, continued to experience significant operating losses, a trend consistent since its inception. Despite these losses, DexCom demonstrated revenue growth in its product segment, driven by increased sales volume of its SEVEN PLUS and early adoption of its newer G4 PLATINUM system, which received FDA approval shortly after the reporting period. The company's balance sheet shows a decrease in total assets compared to the prior year-end, primarily due to a reduction in marketable securities, while cash and cash equivalents increased. Significant investments in research and development and selling, general, and administrative expenses continue to outpace revenue growth, contributing to the ongoing net loss. DexCom highlighted its ongoing collaboration efforts with strategic partners in the diabetes technology space and the recent acquisition of SweetSpot to enhance its data management capabilities. Management expressed confidence in its liquidity position, projecting sufficient funds to cover operations through at least September 30, 2013.

    Nov 1, 2012
  43. 2012-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2012

    DexCom, Inc. (DXCM) reported its financial results for the quarter ended June 30, 2012. The company continues to operate at a net loss, as is typical for early-stage medical device companies focused on growth and development. Revenue showed an increase year-over-year, driven by product sales, which is a positive sign for market acceptance of their continuous glucose monitoring (CGM) systems. However, operating expenses, particularly in research and development and selling, general, and administrative functions, also increased significantly, contributing to the overall net loss. The company secured a CE Mark for its G4 system, allowing for commercialization in the European Union and other countries, though U.S. FDA approval is still pending. The company's liquidity appears adequate for the near term, with substantial cash and marketable securities. A key event during the quarter was the acquisition of SweetSpot, a healthcare IT company, aimed at enhancing data aggregation and analysis capabilities. Despite ongoing efforts to secure third-party reimbursement and navigate a complex regulatory environment, DexCom's path to profitability remains dependent on achieving broader market adoption and favorable reimbursement policies.

    Aug 6, 2012
  44. 2012-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2012

    DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended March 31, 2012. The company reported total revenue of $20.1 million, an increase from $14.2 million in the prior year's comparable quarter, primarily driven by a rise in product revenue to $18.6 million. Despite revenue growth, the company continued to incur significant operating losses, with an operating loss of $15.4 million for the quarter, widening from $11.9 million in the first quarter of 2011. This was mainly due to increased investments in research and development and selling, general, and administrative expenses. Financially, DexCom ended the quarter with $5.1 million in cash and cash equivalents and $65.1 million in short-term marketable securities, providing a total of $70.2 million in liquid assets. The company also completed the acquisition of SweetSpot Diabetes Care, Inc. on March 6, 2012, which is expected to enhance its data management capabilities for diabetes devices. Management believes its current working capital is sufficient to fund operations through at least March 31, 2013, but acknowledges the need for future financing.

    May 2, 2012
  45. 2011-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2011

    DexCom, Inc. (DXCM) reported its quarterly results for the period ended September 30, 2011. The company, a medical device firm focused on continuous glucose monitoring (CGM) systems, demonstrated significant revenue growth in both its product and development grant segments. For the three months ended September 30, 2011, total revenue increased to $18.25 million from $11.66 million in the prior year period. The company's product revenue grew by approximately 53% year-over-year, indicating increasing market adoption of its SEVEN PLUS system. Despite revenue growth, the company continued to operate at a net loss, reporting a net loss of $13.28 million for the quarter. This was largely due to increased operating expenses, particularly in research and development and selling, general, and administrative functions, reflecting ongoing investment in product development and commercialization efforts. The company ended the quarter with a healthy cash position of $17.52 million and significant short-term marketable securities, providing liquidity for future operations.

    Nov 2, 2011
  46. 2011-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2011

    DEXCOM INC. (DXCM) reported its Q2 2011 financial results, showcasing strong revenue growth and significant improvements in gross margin. For the quarter ended June 30, 2011, total revenue increased by 81.7% year-over-year to $21.4 million, driven by a 67.8% increase in product revenue to $15.2 million. This growth was fueled by increased sales volume of their durable systems and disposable sensors, along with higher average per-unit selling prices. The company also benefited from a substantial increase in development grant and other revenues, largely due to a $4.0 million milestone payment received from Animas. Gross margin improved significantly to 55.4% from 38.3% in the prior year's comparable quarter, reflecting increased revenue and better manufacturing absorption. Despite the strong top-line performance and improved profitability at the gross level, the company continued to operate at a net loss, reporting a net loss of $7.4 million for the quarter. Operating expenses, particularly research and development and selling, general, and administrative costs, increased to support product development and commercialization efforts. The company's cash position remains robust, with $105 million in cash, cash equivalents, and marketable securities, providing sufficient runway for operations through at least June 30, 2012. Investors should note the ongoing legal battle with Abbott Diabetes Care and the company's reliance on third-party reimbursements for product adoption.

    Aug 3, 2011
  47. 2011-Q1-A

    DEXCOM INC Quarterly Report (Amendment) for Q1 Ended Mar 31, 2011

    This filing is an amendment (Amendment No. 1) to DexCom, Inc.'s Quarterly Report on Form 10-Q for the period ended March 31, 2011. The primary purpose of this amendment is to re-file Exhibit 10.26, an Amendment Number One to a Non-Exclusive Distribution Agreement with RGH Enterprises, Inc., dated March 29, 2011. Certain portions of this exhibit are subject to confidential treatment. Additionally, new certifications from the CEO and CFO, as required by Rule 12b-15 of the Securities Exchange Act of 1934, are included. This filing does not update the financial statements or other disclosures from the original Form 10-Q, but rather addresses specific SEC comments regarding exhibit confidentiality and certifications.

    Jul 1, 2011
  48. 2011-Q1

    DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2011

    DexCom, Inc. reported its financial results for the first quarter ended March 31, 2011. The company, a medical device firm focused on continuous glucose monitoring (CGM) systems, continued to experience revenue growth in its product segment, with product revenue increasing to $13.1 million from $6.8 million in the prior year's comparable quarter. This growth was driven by higher sales volumes and improved average selling prices for its durable systems and disposable sensors. However, the company also saw a decrease in development grant and other revenues, largely due to extended development and regulatory timelines with partners like Edwards and Animas. Despite the revenue increase, DexCom reported an operating loss and a net loss for the quarter. The company's R&D expenses rose due to increased development efforts for future products, and SG&A expenses also increased to support growth. Management remains focused on commercialization efforts for its SEVEN PLUS system and further product development, anticipating continued losses in the near future. The company believes its current liquidity position is sufficient to fund operations through at least March 31, 2012, but acknowledges the potential need for future financing.

    May 3, 2011
  49. 2010-Q3

    DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2010

    DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended September 30, 2010, on November 4, 2010. The filing highlights the company's continued focus on its continuous glucose monitoring (CGM) systems, specifically the SEVEN PLUS. While product revenue showed significant year-over-year growth, driven by increased sales volume, the company also reported substantial operating losses and an accumulated deficit. Key financial activities during the period included the conversion of all outstanding convertible senior notes, which eliminated long-term debt but resulted in a significant loss on extinguishment. The company also successfully completed a follow-on public stock offering in January 2010, raising approximately $33.0 million. Despite these capital-raising efforts, DexCom anticipates continued losses in the foreseeable future due to ongoing investments in research and development, sales, and marketing activities. Management believes current cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next twelve months, but potential future capital needs remain a consideration.

    Nov 4, 2010
  50. 2010-Q2

    DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2010

    DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended June 30, 2010, reporting significant revenue growth in its core product segment. Product revenue more than doubled year-over-year for both the three-month and six-month periods, indicating increasing market adoption of its continuous glucose monitoring systems. This top-line growth is encouraging, though the company continues to operate at a net loss, which is typical for companies in this development and commercialization stage. Financially, DexCom saw an increase in cash and cash equivalents, largely driven by financing activities including a follow-on public offering in January 2010. However, the company also reported a substantial loss on the extinguishment of convertible debt due to exchanges made during the period, impacting the bottom line. The company's liquidity appears sufficient for the next twelve months, but future funding needs remain a consideration as it continues to invest in research, development, and commercialization efforts. Investors should monitor the company's ability to achieve profitability while managing its ongoing investment in innovation and market expansion.

    Aug 3, 2010